Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin degludec/insulin aspart - Novo Nordisk

Drug Profile

Insulin degludec/insulin aspart - Novo Nordisk

Alternative Names: DegludecPlus; IDegAsp; Insulin aspart/insulin degludec; Insulin aspart/NN1250; Insulin Degludec/Insulin Aspart 15; NN1045; NN1250/insulin aspart; NN5401; Ryzodeg; SIAC; Soluble insulin analogue combination

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 02 Oct 2018 Efficacy data from the phase III Step by Step trial in Type-2 diabetes mellitus released by Novo Nordisk
  • 31 Jan 2018 Novo Nordisk plans a regulatory post marketing surveillance study for Type 1 and 2 diabetes mellitus in South Korea , (NCT03416855)
  • 24 Dec 2017 Novo Nordisk completes a phase III trial in Type-2 diabetes mellitus in USA, Algeria, Czech Republic, India, Russia, Serbia and Turkey (SC) (NCT02906917)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top